New Delhi | Jagran News Desk: The All India Institute for Medical Sciences (AIIMS) Delhi will start enrolling healthy volunteers for the clinical human trials of India's coronavirus vaccine candidate Covaxin from Monday after a hospital panel gave its go-ahead. Covaxin is India's Covid-19 vaccine candidate being developed by Indian company Bharat Biotech International Ltd in coordination with the Indian Council for Medical Research (ICMR).

"The AIIMS Ethics Committee gave its approval for starting the human clinical trial of the indigenously developed Covaxin today. Healthy volunteers having no comorbid conditions and without a history of COVID-19, aged more than 18 years and less than 55 years, would be eligible to participate in the randomised, double-blind, placebo-controlled clinical trial," news agency PTI quoted Dr Sanjay Rai, Professor at the Centre for Community Medicine at AIIMS as saying.

The ICMR has selected 12 sites, including AIIMS-Delhi, for phases I and II of the clinical human trials of Covaxin. In phase-I human trials, as many as 375 volunteers of which 100 would be from AIIMS Delhi, will be administered the Covaxin doses.

"Few volunteers have already registered for the trial. We would start the screening of the individuals and evaluate their health condition from Monday onwards before vaccinating them," Rai said.

Anybody willing to participate in the trial can send an email to or an SMS to or call on 7428847499, he said. The institute may also put up these contact details on its website. According to Rai, the Ethics Committee had raised few concerns in the protocol submitted for carrying out of the trial.

(With PTI inputs)

Posted By: Shashikant Sharma